Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and ...

Blockbuster weight-loss and diabetes drugs Wegovy and Ozempic are no longer in shortage, the US Food and Drug Administration ...

Adults with type 2 diabetes may have a higher risk for developing nonarteritic anterior ischemic optic neuropathy while using ...

Shares of Eli Lilly and Company (NYSE:LLY – Get Free Report) have been assigned a consensus recommendation of “Moderate Buy” from the twenty-one brokerages that are presently covering the stock, ...

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research ...

Strategic Financial Concepts LLC lifted its position in shares of Eli Lilly and Company (NYSE:LLY – Free Report) by 67.7% during the fourth quarter, according to the company in its most recent filing ...

Aristotle Atlantic’s Focus Growth Composite posted a total return of 5.05% gross of fees, underperforming the 7.07% total return of the Russell 1000 Growth Index.

Trulicity sales were $5.46 billion in the first nine months of 2023 - a slight decline on the same period of 2022 that Lilly said was down to shortages, as well as increased competition in the market.